You will be shown the abstract of a medical clinical trial report. Your task is to extract all the findings from this report into a JSON array. Each finding should contain the following five elements:

- Intervention: The medical intervention being tested. This should be a text span copied from the input passage.
- Comparator: The baseline against which the intervention is being evaluated. This should be a text span copied from the input passage. If no comparator is reported, set to `null`.
- Outcome: The medical outcome whose effect is being measured. This should be a text span copied from the input passage.
- Effect: The effect of the intervention on the outcome, relative to the comparator. The effect should be one of the following three values: ("significantly increased", "significantly decreased", "no significant difference").
- Evidence: The evidence for the effect. This should be a text span copied from the input passage.

Please format your output as a JSON array. Each entry in the output should be an array containing the 5 elements listed above, in the following order: [<intervention>, <comparator>, <outcome>, <effect>, <evidence>].

For example, an output with two findings might read:
```
[["aspirin", "placebo", "headache severity", "significantly decreased", "Mean headache severity was significantly decreased in the aspirin group compared to the placebo group (p < 0.05)."], ["aspirin", "placebo", "weight loss", "no significant difference", "We did not observe any difference in weight loss between the group given aspirin relative to the control group"]]
```

There are 9 finding(s) in the abstract below. Please extract them. Output only the JSON array with these 9 findings. Do not include any additional text.

Abstract:
ABSTRACT: The objective of this study is to assess patients' satisfaction with migraine treatment with frovatriptan (F) or zolmitriptan (Z), by preference questionnaire. 133 subjects with a history of migraine with or without aura (IHS criteria) were randomized to F 2.5 mg or Z 2.5 mg. The study had a multicenter, randomized, double-blind, cross-over design, with each of the two treatment periods lasting no more than 3 months. At the end of the study, patients were asked to assign preference to one of the treatments (primary endpoint). The number of pain-free (PF) and pain-relief (PR) episodes at 2 h, and number of recurrent and sustained pain-free (SPF) episodes within 48 h were the secondary study endpoints. Seventy-seven percent of patients expressed a preference. Average score of preference was 2.9 ± 1.3 (F) versus 3.0 ± 1.3 (Z; p = NS). Rate of PF episodes at 2 h was 26% with F and 31% with Z (p = NS). PR episodes at 2 h were 57% for F and 58% for Z (p = NS). Rate of recurrence was 21 (F) and 24% (Z; p = NS). Time to recurrence within 48 h was better for F especially between 4 and 16 h (p < 0.05). SPF episodes were 18 (F) versus 22% (Z; p = NS). Drug-related adverse events were significantly (p < 0.05) less under F (3 vs. 10). In conclusion, our study suggests that F has a similar efficacy of Z, with some advantage as regards tolerability and recurrence.

Findings:
[["frovatriptan (F)", "zolmitriptan (Z)", "Average score of preference", "no significant difference", "Average score of preference was 2.9\u0026nbsp;\u00b1\u0026nbsp;1.3 (F) versus 3.0\u0026nbsp;\u00b1\u0026nbsp;1.3 (Z; p\u0026nbsp;=\u0026nbsp;NS)."], ["frovatriptan (F)", "zolmitriptan (Z)", "Average score of preference", "no significant difference", "verage score of preference was 2.9\u00a0\u00b1\u00a01.3 (F) versus 3.0\u00a0\u00b1\u00a01.3 (Z; p\u00a0=\u00a0NS)."], ["frovatriptan (F)", "zolmitriptan (Z)", "Rate of pain-free (PF) episodes at 2\u0026nbsp;h", "no significant difference", "Rate of PF episodes at 2\u0026nbsp;h was 26% with F and 31% with Z (p\u0026nbsp;=\u0026nbsp;NS)."], ["frovatriptan (F)", "zolmitriptan (Z)", "Rate of recurrence", "no significant difference", "Rate of recurrence was 21 (F) and 24% (Z; p\u0026nbsp;=\u0026nbsp;NS)."], ["frovatriptan (F)", "zolmitriptan (Z)", "Rate of recurrence", "no significant difference", "Rate of recurrence was 21 (F) and 24% (Z; p\u00a0=\u00a0NS)."], ["frovatriptan (F)", "zolmitriptan (Z)", "Time to recurrence within 48\u0026nbsp;h", "significantly increased", "Time to recurrence within 48\u0026nbsp;h was better for F especially between 4 and 16\u0026nbsp;h (p\u0026nbsp;\u0026lt;\u0026nbsp;0.05)."], ["frovatriptan (F)", "zolmitriptan (Z)", "Time to recurrence within 48\u0026nbsp;h", "significantly increased", "Time to recurrence within 48\u00a0h was better for F especially between 4 and 16\u00a0h (p\u00a0\u003c\u00a00.05)."], ["frovatriptan (F)", "zolmitriptan (Z)", "Drug-related adverse events", "significantly decreased", "Drug-related adverse events were significantly (p\u0026nbsp;\u0026lt;\u0026nbsp;0.05) less under F (3 vs. 10)."], ["frovatriptan (F)", "zolmitriptan (Z)", "Drug-related adverse events", "significantly decreased", "Drug-related adverse events were significantly (p\u00a0\u003c\u00a00.05) less under F (3 vs. 10)."]]